Recombinant Anti-Rb (phospho S780) antibody [EPR182(N)] (ab173289)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR182(N)] to Rb (phospho S780)
- Suitable for: Dot blot, IHC-P, WB
- Reacts with: Human
Overview
-
Product name
Anti-Rb (phospho S780) antibody [EPR182(N)]
See all Rb primary antibodies -
Description
Rabbit monoclonal [EPR182(N)] to Rb (phospho S780) -
Host species
Rabbit -
Tested Applications & Species
Application Species IHC-P HumanWB Human -
Immunogen
Synthetic peptide (the amino acid sequence is considered to be commercially sensitive) within Human Rb aa 750-850 (phospho S780) (Cysteine residue). The exact sequence is proprietary.
Database link: P06400 -
Positive control
- Jurkat cell lysate; Human thyroid gland carcinoma and testis tissues.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR182(N) -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Compatible Secondaries
-
Isotype control
-
Positive Controls
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab173289 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Tested applications are guaranteed to work and covered by our Abpromise guarantee.
Predicted to work for this combination of applications and species but not guaranteed.
Does not work for this combination of applications and species.
Application | Species |
---|---|
ICC |
Human
|
IHC-P |
Human
|
WB |
Human
|
Application | Abreviews | Notes |
---|---|---|
Dot blot |
1/1000.
|
|
IHC-P | (1) |
1/100. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
|
WB |
1/10000. Predicted molecular weight: 106 kDa.
|
Notes |
---|
Dot blot
1/1000. |
IHC-P
1/100. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol. |
WB
1/10000. Predicted molecular weight: 106 kDa. |
Target
-
Function
Key regulator of entry into cell division that acts as a tumor suppressor. Promotes G0-G1 transition when phosphorylated by CDK3/cyclin-C. Acts as a transcription repressor of E2F1 target genes. The underphosphorylated, active form of RB1 interacts with E2F1 and represses its transcription activity, leading to cell cycle arrest. Directly involved in heterochromatin formation by maintaining overall chromatin structure and, in particular, that of constitutive heterochromatin by stabilizing histone methylation. Recruits and targets histone methyltransferases SUV39H1, KMT5B and KMT5C, leading to epigenetic transcriptional repression. Controls histone H4 'Lys-20' trimethylation. Inhibits the intrinsic kinase activity of TAF1. Mediates transcriptional repression by SMARCA4/BRG1 by recruiting a histone deacetylase (HDAC) complex to the c-FOS promoter. In resting neurons, transcription of the c-FOS promoter is inhibited by BRG1-dependent recruitment of a phospho-RB1-HDAC1 repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex (By similarity). In case of viral infections, interactions with SV40 large T antigen, HPV E7 protein or adenovirus E1A protein induce the disassembly of RB1-E2F1 complex thereby disrupting RB1's activity. -
Tissue specificity
Expressed in the retina. -
Involvement in disease
Childhood cancer retinoblastoma
Bladder cancer
Osteogenic sarcoma -
Sequence similarities
Belongs to the retinoblastoma protein (RB) family. -
Domain
The Pocket domain binds to the threonine-phosphorylated domain C, thereby preventing interaction with heterodimeric E2F/DP transcription factor complexes. -
Post-translational
modificationsPhosphorylated by CDK6 and CDK4, and subsequently by CDK2 at Ser-567 in G1, thereby releasing E2F1 which is then able to activate cell growth. Dephosphorylated at the late M phase. SV40 large T antigen, HPV E7 and adenovirus E1A bind to the underphosphorylated, active form of pRb. Phosphorylation at Thr-821 and Thr-826 promotes interaction between the C-terminal domain C and the Pocket domain, and thereby inhibits interactions with heterodimeric E2F/DP transcription factor complexes. Dephosphorylated at Ser-795 by calcineruin upon calcium stimulation. CDK3/cyclin-C-mediated phosphorylation at Ser-807 and Ser-811 is required for G0-G1 transition. Phosphorylated by CDK1 and CDK2 upon TGFB1-mediated apoptosis.
N-terminus is methylated by METTL11A/NTM1 (By similarity). Monomethylation at Lys-810 by SMYD2 enhances phosphorylation at Ser-807 and Ser-811, and promotes cell cycle progression. Monomethylation at Lys-860 by SMYD2 promotes interaction with L3MBTL1.
Acetylation at Lys-873 and Lys-874 regulates subcellular localization, at least during keratinocytes differentiation. -
Cellular localization
Nucleus. - Information by UniProt
-
Database links
- Entrez Gene: 5925 Human
- Omim: 614041 Human
- SwissProt: P06400 Human
- Unigene: 408528 Human
-
Alternative names
- Exon 17 tumor GOS561 substitution mutation causes premature stop antibody
- GOS563 exon 17 substitution mutation causes premature stop antibody
- OSRC antibody
see all
Images
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Rb (phospho S780) antibody [EPR182(N)] (ab173289)
Immunohistochemical analysis of paraffin-embedded Human colon tissue labeling Rb (phospho S780) with ab173289 at 1/100 dilution,followed by Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/500 dilution.
Nucleus staining on normal human colon.
Counter stained with Hematoxylin.
Secondary antibody only control:Used PBS instead of primary antibody,secondary antibody is ab97051 at 1/500 dilution.
Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
-
All lanes : Anti-Rb (phospho S780) antibody [EPR182(N)] (ab173289) at 1/50000 dilution
Lane 1 : Jurkat (Human T cell leukemia T lymphocyte) serum starved for 44 h. Whole cell lysates
Lane 2 : Jurkat (Human T cell leukemia T lymphocyte) serum starved for 24 h. Then 10% FBS incubated for 20 h. Whole cell lysates
Lane 3 : Jurkat (Human T cell leukemia T lymphocyte) serum starved for 24 h. Then 10% FBS incubated for 20 h. Whole cell lysates Then the membrane was incubated with phosphatase.
Lysates/proteins at 15 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution
Predicted band size: 106 kDa
Observed band size: 106 kDa
Exposure time: 1 minuteBlocking and diluting buffer and concentration: 5% NFDM/TBST.
-
Lane 1 : Anti-Rb (phospho S780) antibody [EPR182(N)] (ab173289) at 1/20000 dilution
Lane 2 : Anti-Rb (phospho S780) antibody [EPR182(N)] (ab173289)
Lane 1 : K562 (Human chronic myelogenous leukemia cell line from bone marrow) whole cell lysate
Lane 2 : K562(Human chronic myelogenous leukemia cell line from bone marrow) whole cell lysate, serum starved for 2 days
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/50000 dilution
Predicted band size: 106 kDaBlocking/Dilution buffer:5% NFDM/TBST
Exposure time:1 minute
-
All lanes : Anti-Rb (phospho S780) antibody [EPR182(N)] (ab173289) at 1/5000 dilution
Lane 1 : K562 (Human chronic myelogenous leukemia cell line from bone marrow) whole cell lysate
Lane 2 : Calyculin A treated K562(Human chronic myelogenous leukemia cell line from bone marrow) whole cell lysate
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution
Predicted band size: 106 kDaBlocking/Dilution buffer:NFDM/TBST
Ab173289: anti- Rb (phospho S780);
Ab184796: anti- Rb (phospho S807);
Ab181616: anti-Rb
-
Dot blot analysis of Rb (phospho S780) peptide (Lane 1),Rb(non-phospho) peptide (Lane 2) with ab173289 at a dilution of 1/1000.ab97051 (Peroxidase conjugated goat anti-rabbit IgG (H+L) was used as the secondary antibody at a dilution of 1/1000.
Blocking and dilution buffer:5% NFDM/TBST.
Exposure time:3 minutes
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Rb (phospho S780) antibody [EPR182(N)] (ab173289)
Immunohistochemical analysis of paraffin-embedded Lung squamous cell carcinoma labeling Rb (phospho S780) with ab173289 at 1/100 dilution,followed by Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/500 dilution.
Nucleus staining on tumor cells of lung squamous cell carcinoma.
Counter stained with Hematoxylin.
Secondary antibody only control:Used PBS instead of primary antibody,secondary antibody is ab97051 at 1/500 dilution.
Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
-
All lanes : Anti-Rb (phospho S780) antibody [EPR182(N)] (ab173289) at 1/1000 dilution
Lane 1 : Jurkat cell lysate
Lane 2 : Jurkat cell lysate treated with Lambda Phosphatase
Lysates/proteins at 10 µg per lane.
Predicted band size: 106 kDa -
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Rb (phospho S780) antibody [EPR182(N)] (ab173289)
Immunohistochemical analysis of paraffin-embedded Human thyroid gland carcinoma tissue labeling Rb with ab173289 at 1/50 dilution.
Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Rb (phospho S780) antibody [EPR182(N)] (ab173289)
Immunohistochemical analysis of paraffin-embedded Human testis tissue labeling Rb with ab173289 at 1/50 dilution.
Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
Protocols
Datasheets and documents
References (9)
ab173289 has been referenced in 9 publications.
- Li S et al. Pan-cancer analysis reveals synergistic effects of CDK4/6i and PARPi combination treatment in RB-proficient and RB-deficient breast cancer cells. Cell Death Dis 11:219 (2020). PubMed: 32249776
- Chen JJ et al. Antipsychotic agent pimozide promotes reversible proliferative suppression by inducing cellular quiescence in liver cancer. Oncol Rep 42:1101-1109 (2019). PubMed: 31322218
- Sun Y et al. Potent anti-tumor efficacy of palbociclib in treatment-naïve H3.3K27M-mutant diffuse intrinsic pontine glioma. EBioMedicine 43:171-179 (2019). PubMed: 31060906
- Huang H et al. RIPK1 Inhibition Enhances Pirarubicin Cytotoxic Efficacy through AKT-P21-dependent Pathway in Hepatocellular Carcinoma. Int J Med Sci 15:1648-1657 (2018). PubMed: 30588188
- Luo Y et al. ß-catenin nuclear translocation induced by HIF-1a overexpression leads to the radioresistance of prostate cancer. Int J Oncol 52:1827-1840 (2018). PubMed: 29658569
- Yu P et al. Androgen-independent LNCaP cells are a subline of LNCaP cells with a more aggressive phenotype and androgen suppresses their growth by inducing cell cycle arrest at the G1 phase. Int J Mol Med 40:1426-1434 (2017). PubMed: 28901378
- Kero D et al. Regulation of proliferation in developing human tooth germs by MSX homeodomain proteins and cyclin-dependent kinase inhibitor p19INK4d. Organogenesis 13:141-155 (2017). PubMed: 28933666
- Zeng LS et al. Overexpressed HDAC4 is associated with poor survival and promotes tumor progression in esophageal carcinoma. Aging (Albany NY) 8:1236-49 (2016). WB . PubMed: 27295551
- Pozner A et al. Cell-specific Kaiso (ZBTB33) Regulation of Cell Cycle through Cyclin D1 and Cyclin E1. J Biol Chem 291:24538-24550 (2016). PubMed: 27694442